Alnylam Pharma (ALNY) Tops Q1 EPS by 1c

Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.25), $0.01 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $19 million versus the consensus estimate of $23.65 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
• TJX stock drops as profit outlook falls short of analyst estimates
• John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c